orodispersible tablet
Recently Published Documents





Pratiksha S. Deore ◽  
Yashpal M. More ◽  
Avish D. Maru

The aim of present work is to formulate and develop tablets of promethazine HCL.by using various superdisintegrating agent by direct compression method. The main objective of the study is to increase rapid onset of action of promethazine HCL in the treatment of nausea and vomiting. The orodispersible tablet of promethazine hcl is were prepared by direct compression method. Using different concentration of Crospovidone, croscarmellose sodium Mannitol, lactose, maltose, mg. stearate. The tablet was evaluated by various parameters and result are found to be satisfactory.

Amitkumar M. Lokade ◽  
Priya G. Shete ◽  
Neha G. Shete ◽  
Deepak S. Khobragade ◽  
Awdhut D. Pimpale ◽  

Objective iof ithe ipresent iwork iis ito idevelop iorodispersible itablets iof iSalbutamol i ito iimprove ibioavailability, idisintegration itime, idissolution iefficacy iand ipatient icompliance. iOrodispersible itablets iare ithe ifast igrowing iand ihighly iaccepted idrug idelivery isystem iin inow idays imainly ito iimprove ipatient icompliance. iOrodispersible itablets ihave inumber iof iadvantages iover iconventional idosage iforms, ibecause iof ithat iOrodispersible itablets ihave iemerged ias ian ialternative ito iconventional idosage iforms. Orodispersible itablets idissolve ior idisintegrates iinstantly ion ithe ipatient itongue ior ibuccal imucosa. iOrodispersible itablets iof isolbutamol i iwere iprepared iusing isuperdisintegrants, iCrospovidone,Mannitol (Pearlitol iSD-200), ias idiluents iby idirect icompression imethod. iNine iformulations iwere iprepared iusing ithe isuperdisintegrants iat ilower, iintermediate i& ihigher iconcentration. iMannitol iis iused ito ienhance ithe iorganoleptic iproperties iof itablets. iTablets iwere ievaluated ifor iuniformity iof iweight, ihardness, ifriability, iwater iabsorption iratio, idispersion itime, idisintegration itime iand iin ivitro idrug irelease. iAll ithe iformulations ishowed idisintegration itime iless ithan i33 mins iand idrug irelease iby idissolution i(100% iat ithe iend iof i10 imins).

2021 ◽  
Michael Ding ◽  
Syazeddy Samani ◽  
Riad Alame ◽  
Sophie Houghton ◽  
Jenny Roylance ◽  

2021 ◽  
Vol 12 (10) ◽  
pp. 7-12
Arpana Maurya ◽  
Dilip kumar Gupta ◽  
Munendra Mohan Varshaney

Orodispersible tablets (ODTs) are novel drug delivery systems that have the potential to significantly affect conventional dosage forms in terms of patient compliance, convenience, bioavailability, and time to action. Despite the fact that significant research has gone into developing ODT formulations and technologies, in order to produce newer, more expense technologies and better items, more research is needed in these major destinations. Because of the availability of new technologies, as well as good market acceptance and patient compliance, the potential of dosage forms is attractive. Pharmaceutical companies can use ODTs for new product lines or first-to-market products, which is a factor in technology. With the continuing development of new pharmaceutical excipients, more unique ODT technologies are likely to occur soon. Method -For the orodispersible tablet optimized formulation, a direct compression method was used. Result: The pure dosage calibration curve was created by dissolving the medication in ethanol and measuring the absorbance with a UV spectrophotometer set at 243.5 nm. The value of the slope was 1.025. Light microscopy was used to predict the size of teneligliptin particles. The average length and breadth of drug particles were 2.10 µm and 1.14µm. In-vitro drug release study profile of formulation demonstrated around 71 % of the drug diffused in 60 min., while the formulation 85 % of the rug release in 60 min.

2021 ◽  
Vol 2 ◽  
Eliézer K. N’Goran ◽  
Özkan Yalkinoglu ◽  
Elly Kourany-Lefoll ◽  
Aliona Tappert ◽  
Brooke Hayward ◽  

IntroductionTwo novel formulations of praziquantel (PZQ) and Levo-(L-)PZQ (arpraziquantel) have been developed for the treatment of schistosomiasis in preschool-age children and infants.MethodsThis open-label, dose-finding Phase 2 study assessed the efficacy and safety of PZQ formulations in children and infants infected with Schisostoma mansoni in Côte d’Ivoire. In Part 1, 420 children aged 2.1–6.9 years (weight 10.0–29.9 kg) were enrolled and randomized to one of 7 treatment arms (n=60 per arm): commercially available racemate (rac)-PZQ at 3x20 mg/kg or 40 mg/kg (treatment arms 1 and 2); rac-PZQ orodispersible tablet (ODT) at 40 mg/kg or 60 mg/kg (treatment arms 3 and 4); or L-PZQ ODT at 30 mg/kg, 45 mg/kg, or 60 mg/kg (treatment arms 5, 6, and 7). The optimal formulation and dose identified (L-PZQ ODT 50 mg/kg) was used in Part 2, which enrolled 24 infants aged 6–24 months (weight 7.5–14.8 kg). Infants were treated in an age-staggered approach: age 13–24 months (treatment arm 8, n=20) and age 6–12 months (treatment arm 9, n=4). The primary endpoint was clinical cure rate (CR) demonstrated by the Kato–Katz method 14–21 days post-treatment. Secondary endpoints included CR by point-of-care circulating cathodic antigen, egg reduction rate (ERR), and adverse events (AEs).ResultsIn Part 1, CRs ≥70% were achieved in all treatment arms and were highest with L-PZQ ODT 60 mg/kg (89.7%), rac-PZQ 3x20 mg/kg (89.5%), and L-PZQ ODT 45 mg/kg (86.0%). In Part 2, CRs were >90%. All treatment arms had ERRs >95%. Treatment-related AEs were reported by 71 participants (16.0%) and were similar across treatment arms; most were mild and transient. The most common treatment-emergent AEs were laboratory abnormalities. No deaths or discontinuation due to treatment-emergent AEs were reported and no new safety concerns were identified.ConclusionNew rac-PZQ and L-PZQ ODT formulations used as single-dose therapy against S. mansoni demonstrated acceptable overall efficacy and safety in preschool-age children and infants, warranting further studies in this population.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT02806232; Pan African Clinical Trials Registry, identifier PACTR201604001493593.

Dysphagia ◽  
2021 ◽  
Philipp Schreiner ◽  
Thomas Greuter ◽  
Aurora Tatu ◽  
Dagmar I. Keller ◽  
Alex Straumann ◽  

AbstractSince most pharmacological treatments in case of esophageal food impaction (EFI) are unsuccessful, an endoscopy is usually required to resolve EFI. We present the first results of a budesonide orodispersible tablet (BOT) as a medical treatment option before endoscopy. We evaluated all patients with a suspected EFI to receive BOT before emergent endoscopy at a tertiary hospital between March 2019 and June 2020. A total of eight patients received BOT before endoscopy. Mean age was 50.1 years and 87.5% were male. In 38% (3/8) of patients the EFI resolved without endoscopic intervention. No adverse events occurred. After endoscopy, a diagnosis of EoE was established in 75%. This case series demonstrate the potential of BOT as medical rescue therapy in case of EFI.

2021 ◽  
pp. 36-38
Purnima Rai ◽  
Braj Nandan Kishor ◽  
Pooja Pradhan

In this postulations we think about Surface Solid Dispersion and Oro dispersible tablet for upgrade of disintegration rate of valsartan. The medications having low solvency, the disintegration of these medications is rate constraining advance in their bioavailability in oral measurements frames. To defeat this number of innovations are accessible. Among them surface solid dispersion and oro dispersible tablets are two promising systems. Surface solid dispersion is a method for scattering at least one xing on a water solvent transporter of to a great degree high surface territory to accomplish expanded bioavailability and disintegration rates of insoluble medications, and oro dispersible tablets are one of the novel oral medication conveyance framework that break down or scatter rapidly in almost no time after situation in month without water.

2021 ◽  
Vol 11 (4) ◽  
pp. 41-47
Ria Shah ◽  
Disha Patel ◽  
Dhruvanshi Kothari ◽  
Hetvi Shah ◽  
Aishwarya Chavda ◽  

Orodispersible tablets (ODTs) is one such novel approach which helps to increase user acceptance by virtue of rapid disintegration, self-administration without water or chewing. ODTs are solid unit dosage forms like the conventional tablets containing super disintegrants, which help them to disintegrate and/or disperse rapidly in the mouth within few seconds. The orodispersible tablet of Paroxetine hydrochloride was prepared by using direct compression method and the tablet were formulated using various concentration of Kyron T-314 as disintegrating agent, PVP K-30 as binder, F melt Type C as diluent, Sodium Saccharin as sweetening agent, talc as lubricant and Aerosil as glidant respectively. All the batches were prepared according to Factorial design. The prepared tablets were evaluated for various parameters like hardness, dissolution, friability, weight variation, disintegration time. Batch F5 was found to be the best batch as the disintegration time is minimum (26seconds) and better drug release profile. Orodispersible tablets of Paroxetine Hydrochloride were successfully formulated by which first pass metabolism could be avoided and faster onset of action could be achieved.

2021 ◽  
Vol 11 (4) ◽  
pp. 149-156
Suhasis Bhattacharya ◽  
Tanmay Mohanta ◽  
Sujit Das ◽  
Rumpa Basak

The most comfortable and choicely path of drug administration is oral route. Orodispersible tablets bring a revolution among all routes of drug administration as well as oral route of drug administration also. Orodispersible tablets are unit dosage form but it has unique characteristics. It disintegrates in the mouth within a minute for the presence of saliva where the presence of super disintegrates in the preparation. Especially, old and child have no chance to swallow as a result it is very acceptable for them. Migraine is a very well-known irritating condition for adult and female. Migraine is a debilitating and common neurovascular illness associated with symptoms of one-sided headache, nausea with or without vomiting, photophobia and/or phonophobia. But these symptoms are subjective and vary from patient to patient. Orodispersible tablets are most important solution of migraine like emergency condition and helping human by transferring from hell to heaven. Very short half-life, quick disintegration, quick onset of action and better bioavailability brings the orodispersible tablets into the top position of the management of migraine. Sumatriptan, zolmitriptan like drugs are helping their hands to reduce migraine. Lastly, there are lots of drugs are investigating for this purpose and our hope that the orodispersible tablet can give the pioneer and will give the migraine free era to us and our futures. Keywords: Orodispersible tablet, migraine, sumatriptan, super disintegrate, fast dissolving

Rupalben K. Jani ◽  
Gohil Krupa ◽  
Aanal Gandhi ◽  
Vijay Upadhye ◽  
Roshani Pragnesh Amin

The foremost objective of this research was to compare and evaluate natural super disintegrants with synthetic super disintegrants for the preparation of the orodispersible tablet. Tropisetron hydrochloride is widely used as an antiemetic drug, which is a potential drug candidate for developing an orodispersible tablet for quick onset of action. Various formulations were prepared using different concentrations (5%, 7.5%, and 10%) by direct compression method of natural super disintegrants (Banana power and Cassia tora powder) and synthetic super disintegrants (Croscarmellose sodium, Crospovidone, and Sodium starch glycolate). The compatibility studies between the drug and excipients were carried out using FTIR spectroscopy before tablet formulation. The pre-compression parameters were evaluated for additive properties. Standardization of banana powder was done by various parameters like extractive value, ash value, loss on drying, TLC identification test, etc. Post-compression parameters like hardness, weight variation, friability, thickness, the time required for disintegration, wetting time, the release of drug in-vitro, and in-vitro dispersion time of the tablets were evaluated. The disintegration time and in-vitro drug release of optimized formulation (F2) were found to be 4.66±1.15 secs and 99.25±0.15%. The optimized formulation (F2) was subjected to stability studies (40 C& 75 % RH) for one month. The results were shown that natural super disintegrants require less disintegration time as compared to synthetic super disintegrants. Hence present study reveals that the orodispersible tablets prepared using Banana powder and Cassia tora powder is super disintegrants that shown better appearance and rapid disintegration time.

Sign in / Sign up

Export Citation Format

Share Document